ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 654

Applying Systemic Lupus International Collaborating Clinics (SLICC) and Provisional ACR/EULAR Systemic Lupus Erythematosus Classification Criteria in a Cohort of Patients with Undifferentiated Connective Tissue Disease

Kyle Drehmel1, Alan Erickson 1, Bryant England 2 and Michelene Hearth-Holmes 1, 1University of Nebraska Medical Center, Omaha, NE, 2VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: classification criteria, Clinical practice, systemic lupus erythematosus (SLE) and slicc, undifferentiated connective tissue disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Undifferentiated Connective Tissue Disease (UCTD) describes the clinical scenario where a patient demonstrates characteristics of a connective tissue disease but does not meet criteria for a defined CTD. The CTD that is most frequently implicated with UCTD is systemic lupus erythematosus (SLE). In recent years, new classification criteria for SLE have been developed. This study investigates the reclassification of UCTD patients using newly proposed SLE criteria.

Methods: Patients were identified within the Rheumatology and Arthritis Investigational Network (RAIN) database at the University of Nebraska Medical Center. Medical records of all patients were reviewed to confirm fulfillment of proposed classification criteria for UCTD: positive ANA, signs and symptoms of a CTD but not fulfilling the criteria for a defined CTD, and a disease duration of at least one year, including early UCTD. Characteristics at the time of diagnosis with UCTD were collected through medical record review and managed using the REDCap electronic data capture tool. The SLICC and ACR/EULAR criteria for SLE were applied at the time of diagnosis with UCTD. We then compared the proportion of patients reclassified as SLE according to these criteria as well as the specific disease features associated with reclassification as SLE.

Results: A total of 129 patients were included in the study. The majority of patients were female and white (90.7%), and the mean (SD) age at UCTD diagnosis was 43.5 (13.9). When applying the SLICC criteria, 18 patients (14.0%) were reclassified as SLE while 26 patients (20.2%) were reclassified using the ACR/EULAR criteria. Disease features which were associated with reclassification for both SLICC (Table 1) and ACR/EULAR criteria (Table 2) were renal involvement, leukopenia, thrombocytopenia, anti-dsDNA antibody, and hypocomplementemia. Non-scarring alopecia was associated with reclassification as SLE only under the SLICC criteria while the presence of arthritis was associated with reclassification as SLE under the ACR/EULAR criteria.

Conclusion: Both the SLICC and ACR/EULAR criteria exhibit increased sensitivity for SLE classification. The only disease feature associated with reclassification under the ACR/EULAR criteria but not the SLICC criteria was the presence of arthritis. Because arthritis is weighted heavily in this criteria (6 out of 10 points), it will reclassify many patients with this frequent manifestation as SLE.


UCTD Table 1

Comparison made between group reclassified as SLE and group not reclassified according to SLICC criteria. Disease features were evaluated according to the definition provided by the SLICC criteria.
*Includes anticardiolipin, lupus anticoagulant, anti-β2-glycoprotein


UCTD Table 2

Comparison made between group reclassified as SLE and group not reclassified according to ACR/EULAR criteria. Disease features were evaluated according to the definition provided by the ACR/EULAR criteria.
*Includes anticardiolipin, lupus anticoagulant, anti-β2-glycoprotein


Disclosure: K. Drehmel, None; A. Erickson, None; B. England, None; M. Hearth-Holmes, None.

To cite this abstract in AMA style:

Drehmel K, Erickson A, England B, Hearth-Holmes M. Applying Systemic Lupus International Collaborating Clinics (SLICC) and Provisional ACR/EULAR Systemic Lupus Erythematosus Classification Criteria in a Cohort of Patients with Undifferentiated Connective Tissue Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/applying-systemic-lupus-international-collaborating-clinics-slicc-and-provisional-acr-eular-systemic-lupus-erythematosus-classification-criteria-in-a-cohort-of-patients-with-undifferentiated-connect/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/applying-systemic-lupus-international-collaborating-clinics-slicc-and-provisional-acr-eular-systemic-lupus-erythematosus-classification-criteria-in-a-cohort-of-patients-with-undifferentiated-connect/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology